Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients …
Over the last 12 months, insiders at Corcept Therapeutics Incorporated have bought $0 and sold $10.36M worth of Corcept Therapeutics Incorporated stock.
On average, over the past 5 years, insiders at Corcept Therapeutics Incorporated have bought $2.34M and sold $8.48M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 150,000 shares for transaction amount of $3.23M was made by BAKER G LEONARD JR (director) on 2021‑06‑11.
2024-11-11 | Sale | director | 2,200 0.0021% | $59.88 | $131,736 | -4.72% | ||
2024-11-04 | Sale | Chief Development Officer | 3,394 0.0032% | $48.97 | $166,204 | +12.41% | ||
2024-10-01 | Sale | Chief Business Officer | 11,000 0.0113% | $46.28 | $509,080 | +1.86% | ||
2024-10-01 | Sale | Chief Development Officer | 10,000 0.0102% | $46.28 | $462,800 | +1.86% | ||
2024-09-03 | Sale | Chief Development Officer | 10,000 0.0099% | $35.30 | $353,000 | +33.86% | ||
2024-08-26 | Sale | Chief Business Officer | 3,101 0.003% | $35.71 | $110,737 | +29.80% | ||
2024-08-01 | Sale | Chief Development Officer | 10,000 0.0098% | $38.67 | $386,700 | +13.21% | ||
2024-08-01 | Sale | director | 150 0.0001% | $38.50 | $5,775 | +13.21% | ||
2024-07-01 | Sale | Chief Business Officer | 11,000 0.0109% | $32.49 | $357,390 | 0.00% | ||
2024-07-01 | Sale | See Remarks | 5,000 0.0049% | $32.49 | $162,452 | 0.00% | ||
2024-07-01 | Sale | Chief Development Officer | 10,000 0.0099% | $32.49 | $324,900 | 0.00% | ||
2024-07-01 | Sale | director | 2,200 0.0022% | $32.81 | $72,182 | 0.00% | ||
2024-06-03 | Sale | See Remarks | 5,000 0.0046% | $30.18 | $150,916 | +12.52% | ||
2024-06-03 | Sale | Chief Development Officer | 10,000 0.0098% | $32.00 | $320,000 | +12.52% | ||
2024-06-03 | Sale | director | 2,200 0.002% | $30.21 | $66,462 | +12.52% | ||
2024-05-28 | Sale | Chief Business Officer | 11,000 0.0102% | $30.39 | $334,294 | +10.77% | ||
2024-05-28 | Sale | Chief Development Officer | 30,000 0.0292% | $32.00 | $960,000 | +10.77% | ||
2024-05-13 | Sale | See Remarks | 50,000 0.0488% | $28.00 | $1.4M | +25.83% | ||
2024-05-09 | Sale | See Remarks | 7,227 0.0068% | $26.00 | $187,902 | +29.96% | ||
2024-05-02 | Sale | See Remarks | 10,830 0.0109% | $26.00 | $281,580 | +37.59% |
Robb Gary Charles | Chief Business Officer | 22772 0.0217% | $55.82 | 1 | 25 | +72.23% |
ALTA BIOPHARMA PARTNERS II LP | 10 percent owner | 5484063 5.2341% | $55.82 | 2 | 0 | +16.86% |
PENHOET EDWARD | 5484063 5.2341% | $55.82 | 1 | 0 | +78.79% | |
SUTTER HILL VENTURES | 10 percent owner | 5217464 4.9797% | $55.82 | 6 | 0 | +59.94% |
MARDUEL ALIX | 10 percent owner | 5043299 4.8135% | $55.82 | 3 | 0 | +59.16% |
BlackRock | $423.85M | 16.16 | 16.83M | +2.55% | +$10.54M | 0.01 | |
The Vanguard Group | $240.96M | 9.19 | 9.57M | +0.3% | +$711,617.50 | <0.01 | |
Ingalls Snyder Llc | $209.16M | 7.98 | 8.3M | -0.58% | -$1.23M | 9.78 | |
Renaissance Technologies | $179.31M | 6.84 | 7.12M | +5.84% | +$9.89M | 0.29 | |
Parallel Advisors, LLC | $96.12M | 3.67 | 3.82M | +1.26% | +$1.19M | 2.62 |